IZQVF - Addex Indivior expand team up to develop therapies for substance use disorders

• Addex Therapeutics ( NASDAQ: ADXN ) and Indivior ( OTCPK:INVVY ) ( OTCPK:IZQVF ) extended their collaboration on discovering and developing novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates until March 31, 2023.
• Under the amended agreement, Indivior will provide Addex CHF850K in additional research funding.
• The reserved indications, where Addex retains exclusive rights to develop its own independent GABAB PAM program, were also expanded to include chronic cough, in addition to the rights to develop certain retained compounds for Charcot-Marie-Tooth type 1A neuropathy (CMT1A) and pain, Addex said in an Aug. 15 press release.
• "We have advanced the GABAB PAM program into the late stage of clinical candidate selection and are currently selecting compounds for entry into IND enabling studies for both Indivior’s program in substance use disorder and Addex’s independent programs for CMT1A, chronic cough and pain," said said Mikhail Kalinichev, head of Translational Science, Addex.

For further details see: